Aurinia Pharmaceuticals Inc (AUPH)
8.72
-0.14
(-1.58%)
USD |
NASDAQ |
Nov 25, 16:00
8.72
0.00 (0.00%)
After-Hours: 20:00
Aurinia Pharmaceuticals Revenue (TTM): 220.36M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 220.36M |
| June 30, 2024 | 207.10M |
| March 31, 2024 | 191.41M |
| December 31, 2023 | 175.51M |
| September 30, 2023 | 158.85M |
| June 30, 2023 | 160.12M |
| March 31, 2023 | 146.81M |
| December 31, 2022 | 134.03M |
| September 30, 2022 | 129.00M |
| June 30, 2022 | 87.89M |
| March 31, 2022 | 66.32M |
| December 31, 2021 | 45.60M |
| September 30, 2021 | 72.23M |
| June 30, 2021 | 57.59M |
| March 31, 2021 | 51.00M |
| December 31, 2020 | 50.12M |
| September 30, 2020 | 0.117M |
| June 30, 2020 | 0.318M |
| March 31, 2020 | 0.318M |
| December 31, 2019 | 0.318M |
| September 30, 2019 | 0.318M |
| June 30, 2019 | 0.463M |
| March 31, 2019 | 0.463M |
| December 31, 2018 | 0.463M |
| September 30, 2018 | 0.464M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.118M |
| March 31, 2018 | 0.418M |
| December 31, 2017 | 0.418M |
| September 30, 2017 | 0.418M |
| June 30, 2017 | 0.42M |
| March 31, 2017 | 0.146M |
| December 31, 2016 | 0.173M |
| September 30, 2016 | 0.20M |
| June 30, 2016 | 0.226M |
| March 31, 2016 | 0.23M |
| December 31, 2015 | 0.235M |
| September 30, 2015 | 0.246M |
| June 30, 2015 | 0.261M |
| March 31, 2015 | 0.273M |
| December 31, 2014 | 0.278M |
| September 30, 2014 | 0.922M |
| June 30, 2014 | 0.934M |
| March 31, 2014 | 0.948M |
| December 31, 2013 | 0.969M |
| September 30, 2013 | 0.3432M |
| June 30, 2013 | 0.3466M |
| March 31, 2013 | 0.3501M |
| December 31, 2012 | 6.075M |
| September 30, 2012 | 6.109M |
| June 30, 2012 | 6.557M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.117M
Minimum
Sep 2020
220.36M
Maximum
Sep 2024
97.75M
Average
80.06M
Median
Revenue (TTM) Benchmarks
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | 0.411M |
| Xenon Pharmaceuticals Inc | -- |
| ESSA Pharma Inc | -- |
| ImmunoPrecise Antibodies Ltd | 17.73M |